Zocdoc buys Sohar Health in first acquisition after 20-year gap

Zocdoc has acquired Sohar Health, a New York-based insurance verification startup, marking its first acquisition in nearly two decades. The purchase follows a 2025 pilot in which Zocdoc used Sohar’s technology to check millions of patient coverage records.
AlleyWatch reported that Zocdoc tested Sohar as a partner before bringing the company in-house. The move reflects a broader shift among healthtech platforms to embed insurance verification earlier in the patient journey, reducing last-minute surprises and no-shows.
For Zocdoc, which has spent most of its history as a marketplace for doctor appointments, the acquisition suggests a deeper investment in pre-visit workflows. Sohar’s technology could eventually power real-time eligibility checks within Zocdoc’s scheduling flow, though neither company has confirmed specific integration plans.
The deal also highlights how insurance verification is becoming a battleground for patient-facing startups. While enterprise-focused incumbents dominate the space, younger companies are building lighter, API-first tools for digital health platforms. Sohar’s exit—its first reported acquisition—adds to a small but growing list of insurtech startups being snapped up by larger healthtech players.
No financial terms were disclosed. Zocdoc remains privately held.
Sources: alleywatch.com
“The deal signals Zocdoc’s push into pre-visit workflows and suggests that insurance verification is becoming table stakes for patient-facing platforms.”
Read the original reporting
The outlets below did the original reporting.
Related briefs
- Collective X Health raises $3.2M pre-seed to tackle women's health data
- German startup TimeTeller launches saliva test for circadian medicine
- Prime Intellect acquires Seattle AI startup Moondream for inference tech
- Former Apple engineers launch adhesive-free health tracker for watches
- Mosqitter pivots traps into AI surveillance network
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.